Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (12044)
All Articles published online
|
Publishing Process of This Article
|
Aug 14, 2016 (publication date) through Apr 23, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Lo Nigro C, Ricci V, Vivenza D, Granetto C, Fabozzi T, Miraglio E, Merlano MC. Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy. World J Gastroenterol 2016; 22(30): 6944-6954 [PMID: 27570430 DOI: 10.3748/wjg.v22.i30.6944] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v22/i30/6944.htm |
| Number | Citing Articles |
| 1 |
José María Sayagués, Sofía Del Carmen, María Del Mar Abad, Luís Antonio Corchete, Oscar Bengoechea, María Fernanda Anduaga, María Jesús Baldeón, Juan Jesús Cruz, Jose Antonio Alcazar, María Angoso, Marcos González, Jacinto García, Luís Muñoz-Bellvis, Alberto Orfao, María Eugenia Sarasquete. Combined assessment of the TNM stage and BRAF mutational status at diagnosis in sporadic colorectal cancer patients. Oncotarget 2018; 9(35): 24081 doi: 10.18632/oncotarget.25300
|
| 2 |
Johan Gagnière, Aurélien Dupré, Sepideh S. Gholami, Denis Pezet, Thomas Boerner, Mithat Gönen, Thomas P. Kingham, Peter J. Allen, Vinod P. Balachandran, Ronald P. De Matteo, Jeffrey A. Drebin, Rona Yaeger, Nancy E. Kemeny, William R. Jarnagin, Michael I. D’Angelica. Is Hepatectomy Justified for BRAF Mutant Colorectal Liver Metastases?. Annals of Surgery 2020; 271(1): 147 doi: 10.1097/SLA.0000000000002968
|
| 3 |
Leah H. Biller, Deborah Schrag. Diagnosis and Treatment of Metastatic Colorectal Cancer. JAMA 2021; 325(7): 669 doi: 10.1001/jama.2021.0106
|
| 4 |
Ender Dogan, Sedat T Firat, Ramazan Cosar, Oktay Bozkurt, Mevlude Inanc, Metin Ozkan. Efficacy of second-line targeted agents in kras wild metastatic colorectal cancer patients who received prior targeted agent: First anti-epidermal growth factor receptor or vascular endothelial growth factor in right and left colon?. Journal of Oncology Pharmacy Practice 2020; 26(4): 781 doi: 10.1177/1078155219856682
|
| 5 |
Sarah Wedden, Keith Miller, Ian M. Frayling, Teresa Thomas, Alina Chefani, Karolina Miller, Angela Hamblin, Jenny C. Taylor, Corrado D’Arrigo. Colorectal Cancer Stratification in the Routine Clinical Pathway: A District General Hospital Experience. Applied Immunohistochemistry & Molecular Morphology 2019; 27(6): e54 doi: 10.1097/PAI.0000000000000631
|
| 6 |
Alexandra Gherman, Loredana Balacescu, Sinziana Gheorghe-Cetean, Catalin Vlad, Ovidiu Balacescu, Alexandru Irimie, Cosmin Lisencu. Current and New Predictors for Treatment Response in Metastatic Colorectal Cancer. The Role of Circulating miRNAs as Biomarkers. International Journal of Molecular Sciences 2020; 21(6): 2089 doi: 10.3390/ijms21062089
|
| 7 |
Hafeez Afolabi, Salzihan Md Salleh, Zaidi Zakaria, Ch’ng Ewe Seng, Siti Norasikin Binti Mohd Nafil, Ahmad Aizat Bin Abdul Aziz, Yusuf Wada, Ahmad Irekeola, Syed Sameer Aga. A Systematic Review and Meta-analysis on the Occurrence of Biomarker Mutation in Colorectal Cancer among the Asian Population. BioMed Research International 2022; 2022: 1 doi: 10.1155/2022/5824183
|
| 8 |
Mauro Giacomelli, Matilde Monti, Diego Cesare Pezzola, Silvia Lonardi, Mattia Bugatti, Francesco Missale, Rossella Cioncada, Laura Melocchi, Viviana Giustini, Vincenzo Villanacci, Carla Baronchelli, Stefania Manenti, Luisa Imberti, Emanuele Giurisato, William Vermi. Immuno-Contexture and Immune Checkpoint Molecule Expression in Mismatch Repair Proficient Colorectal Carcinoma. Cancers 2023; 15(12): 3097 doi: 10.3390/cancers15123097
|
| 9 |
Swati Sakhuja, Huifeng Yun, Maria Pisu, Tomi Akinyemiju. Availability of healthcare resources and epithelial ovarian cancer stage of diagnosis and mortality among Blacks and Whites. Journal of Ovarian Research 2017; 10(1) doi: 10.1186/s13048-017-0352-1
|
| 10 |
Whole Transcriptome Analysis Identifies TNS4 as a Key Effector of Cetuximab and a Regulator of the Oncogenic Activity of KRAS Mutant Colorectal Cancer Cell Lines. Cells 2019; 8(8): 878 doi: 10.3390/cells8080878
|
| 11 |
Nesreen H. Hafez, Noha Ezzat. Epidermal growth factor receptor expression in colorectal adenocarcinoma and their corresponding metastatic sites. Egyptian Journal of Pathology 2017; 37(2): 244 doi: 10.1097/01.XEJ.0000526543.24249.1
|
| 12 |
Kelsey E. McHugh, Josephine K. Dermawan, Yu‐Wei Cheng, Michael Cruise, Davendra P. S. Sohal, Jordan P. Reynolds. Molecular testing in metastatic colorectal adenocarcinoma cytology cell pellets. Diagnostic Cytopathology 2019; 47(11): 1132 doi: 10.1002/dc.24275
|
| 13 |
Lin Yang, Wen Zhang, Nanfeng Fan, Peiguo Cao, Ying Cheng, Lingjun Zhu, Suxia Luo, Hong Zong, Yuxian Bai, Jianfeng Zhou, Yanhong Deng, Yi Ba, Tianshu Liu, Mayinuer Aili, Xianli Yin, Kangsheng Gu, Guanghai Dai, Jieer Ying, Jianhua Shi, Yajie Gao, Wei Li, Guohua Yu, Liangzhi Xie, Wenlin Gai, Yan Wang, Peng Meng, Yuankai Shi. Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study. eBioMedicine 2024; 100: 104966 doi: 10.1016/j.ebiom.2024.104966
|
| 14 |
Michael Getz, Padmini Rangamani, Pradipta Ghosh. Regulating cellular cyclic adenosine monophosphate: “Sources,” “sinks,” and now, “tunable valves”. WIREs Systems Biology and Medicine 2020; 12(5) doi: 10.1002/wsbm.1490
|
| 15 |
Maurice Michel, Leonard Kaps, Annett Maderer, Peter R. Galle, Markus Moehler. The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy. Cancers 2021; 13(10): 2296 doi: 10.3390/cancers13102296
|
| 16 |
Rafael Pulido, Janire Mingo, Ayman Gaafar, Caroline E. Nunes-Xavier, Sandra Luna, Leire Torices, Javier C. Angulo, José I. López. Precise Immunodetection of PTEN Protein in Human Neoplasia. Cold Spring Harbor Perspectives in Medicine 2019; 9(12): a036293 doi: 10.1101/cshperspect.a036293
|
| 17 |
Laurence Gau, Mathieu Ribeiro, Bruno Pereira, Karine Poirot, Aurélien Dupré, Denis Pezet, Johan Gagnière. Impact of BRAF mutations on clinical outcomes following liver surgery for colorectal liver metastases: An updated meta-analysis. European Journal of Surgical Oncology 2021; 47(11): 2722 doi: 10.1016/j.ejso.2021.05.039
|
| 18 |
Josef Singer, Elias Brauneck, Elisabeth Zwickl-Traxler, Martin Pecherstorfer. Evaluation of personalized cancer therapies based on comprehensive genomic profiling in a middle-sized oncologic center in Austria, the University Clinic Krems. Translational Oncology 2021; 14(5): 101021 doi: 10.1016/j.tranon.2021.101021
|
| 19 |
Hou-Hsien Liu, Chia-Hwa Lee, Yi-Chen Hsieh, Duen-Wei Hsu, Er-Chieh Cho. Multiple myeloma driving factor WHSC1 is a transcription target of oncogene HMGA2 that facilitates colon cancer proliferation and metastasis. Biochemical and Biophysical Research Communications 2021; 567: 183 doi: 10.1016/j.bbrc.2021.06.034
|
| 20 |
Alessandro Ottaiano, Stefania Scala, Nicola Normanno, Maria Napolitano, Monica Capozzi, Anna Maria Rachiglio, Cristin Roma, Anna Maria Trotta, Crescenzo D’Alterio, Luigi Portella, Carmela Romano, Antonino Cassata, Rossana Casaretti, Lucrezia Silvestro, Anna Nappi, Salvatore Tafuto, Antonio Avallone, Alfonso De Stefano, Mario Tamburini, Carmine Picone, Antonella Petrillo, Francesco Izzo, Raffaele Palaia, Vittorio Albino, Alfonso Amore, Andrea Belli, Ugo Pace, Massimiliano Di Marzo, Paolo Chiodini, Gerardo Botti, Gianfranco De Feo, Paolo Delrio, Guglielmo Nasti. Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol. BMC Cancer 2019; 19(1) doi: 10.1186/s12885-019-6109-z
|
| 21 |
María Antonia Lizarbe, Jorge Calle-Espinosa, Eva Fernández-Lizarbe, Sara Fernández-Lizarbe, Miguel Ángel Robles, Nieves Olmo, Javier Turnay. Colorectal Cancer: From the Genetic Model to Posttranscriptional Regulation by Noncoding RNAs. BioMed Research International 2017; 2017: 1 doi: 10.1155/2017/7354260
|
| 22 |
Yuki Morishita, Hiroaki Tanioka, Motoi Asano, Kotomi Tokuyama, Hiroko Okamoto, Tomohisa Okamoto, Takako Oda, Masatoshi Ohta, Masayuki Fukuzawa. Clinical Predictors of Cetuximab for First-Line Therapy of Metastatic Colorectal Cancer: A Single Institutional Retrospective Study. Journal of Cancer Therapy 2017; 8(09): 827 doi: 10.4236/jct.2017.89072
|
| 23 |
Magdalena Cisło, Agata Anna Filip, George Johan Arnold Offerhaus, Bogumiła Ciseł, Karol Rawicz-Pruszyński, Małgorzata Skierucha, Wojciech Piotr Polkowski. Distinct molecular subtypes of gastric cancer: from Laurén to molecular pathology. Oncotarget 2018; 9(27): 19427 doi: 10.18632/oncotarget.24827
|
| 24 |
E. P. Vashkevich, A. A. Migas, A. N. Meleshko, M. A. Matveenko, N. V. Strushkevich, T. V. Shman. Expansion and Activation of Human Natural Killer Cells ex vivo in the Presence of Transgenic Feeder Cells. Cell and Tissue Biology 2020; 14(5): 365 doi: 10.1134/S1990519X20050090
|
| 25 |
Zhu Yufeng, Qi Ming, Wu Dandan. MiR-320d Inhibits Progression of EGFR-Positive Colorectal Cancer by Targeting TUSC3. Frontiers in Genetics 2021; 12 doi: 10.3389/fgene.2021.738559
|
| 26 |
Shin-Yi Chung, Yu-Chan Chang, Dennis Shin-Shian Hsu, Ya-Chi Hung, Meng-Lun Lu, Yi-Ping Hung, Nai-Jung Chiang, Chun-Nan Yeh, Michael Hsiao, John Soong, Yeu Su, Ming-Huang Chen. A G-quadruplex stabilizer, CX-5461 combined with two immune checkpoint inhibitors enhances in vivo therapeutic efficacy by increasing PD-L1 expression in colorectal cancer. Neoplasia 2023; 35: 100856 doi: 10.1016/j.neo.2022.100856
|
| 27 |
I.S. Shponka, I.K. Kharkhalis , O.V. Poslavska . Study of the expression of oncoprotein p53, EGFR in colorectal carcinomas with different proliferative activity. Medicni perspektivi 2023; 28(1) doi: 10.26641/2307-0404.2023.1.275703
|
| 28 |
Nayoung Kim, Daseul Cho, Hyunjin Kim, Sujin Kim, Young‐je Cha, Heidi Greulich, Adam Bass, Hyun‐Soo Cho, Jeonghee Cho. Colorectal adenocarcinoma‐derived EGFR mutants are oncogenic and sensitive to EGFR‐targeted monoclonal antibodies, cetuximab and panitumumab. International Journal of Cancer 2020; 146(8): 2194 doi: 10.1002/ijc.32499
|
| 29 |
Translational Potential of MicroRNAs for Preoperative Staging and Prediction of Chemoradiotherapy Response in Rectal Cancer. Cancers 2019; 11(10): 1545 doi: 10.3390/cancers11101545
|
| 30 |
Fiorella Guadagni, Sofia Cutaia, Giorgio Madonia, Valerio Gristina, Lorena Incorvaia, Lidia Rita Corsini, Daniele Fanale, Claudio Longhitano, Federica Martorana, Juan Lucio Iovanna, Viviana Bazan, Paolo Vigneri. Practical Medical Oncology Textbook. UNIPA Springer Series 2021; : 43 doi: 10.1007/978-3-030-56051-5_4
|
| 31 |
Ryia Illani Mohd Yunos, Nurul Syakima Ab Mutalib, Francis Yew Fu Tieng, Nadiah Abu, Rahman Jamal. Actionable Potentials of Less Frequently Mutated Genes in Colorectal Cancer and Their Roles in Precision Medicine. Biomolecules 2020; 10(3): 476 doi: 10.3390/biom10030476
|
| 32 |
Eleonora Lai, Andrea Pretta, Valentino Impera, Stefano Mariani, Riccardo Giampieri, Laura Casula, Valeria Pusceddu, Pierpaolo Coni, Daniela Fanni, Marco Puzzoni, Laura Demurtas, Pina Ziranu, Gavino Faa, Mario Scartozzi. BRAF-mutant colorectal cancer, a different breed evolving. Expert Review of Molecular Diagnostics 2018; 18(6): 499 doi: 10.1080/14737159.2018.1470928
|
| 33 |
Alessandro Ottaiano, Alfonso De Stefano, Monica Capozzi, Anna Nappi, Chiara De Divitiis, Carmela Romano, Lucrezia Silvestro, Antonino Cassata, Rossana Casaretti, Salvatore Tafuto, Michele Caraglia, Massimiliano Berretta, Guglielmo Nasti, Antonio Avallone. First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis. Frontiers in Pharmacology 2018; 9 doi: 10.3389/fphar.2018.00441
|
| 34 |
Shih‑Chang Chuang, Ching‑Wen Huang, Yi‑Ting Chen, Cheng‑Jen Ma, Hsiang‑Lin Tsai, Tsung‑Kun Chang, Wei‑Chih Su, Wen‑Hung Hsu, Chao‑Hung Kuo, Jaw‑Yuan Wang. Effect of KRAS and NRAS mutations on the prognosis of patients with synchronous metastatic colorectal cancer presenting with liver‑only and lung‑only metastases. Oncology Letters 2020; 20(3): 2119 doi: 10.3892/ol.2020.11795
|
| 35 |
Sumeet Gupta, Vikas Jhawat. Quality by design (QbD) approach of pharmacogenomics in drug designing and formulation development for optimization of drug delivery systems. Journal of Controlled Release 2017; 245: 15 doi: 10.1016/j.jconrel.2016.11.018
|
| 36 |
Nerethika Ravichandiran, Muneesh Kumar Barman, Sai Tejaswi Lavuri, Manjita Srivastava, Shalini Sakthivel, Meenakshi Singh, Kailash Chand, Subash C. Sonkar, Prudhvilal Bhukya. Handbook of Research on Advancements in Cancer Therapeutics. Advances in Medical Diagnosis, Treatment, and Care 2021; : 433 doi: 10.4018/978-1-7998-6530-8.ch015
|
| 37 |
Denaro Nerina, Marco Carlo Merlano. Critical Issues in Head and Neck Oncology. 2021; : 65 doi: 10.1007/978-3-030-63234-2_5
|
| 38 |
Zheying Zhang, Cheng Fang, Yongxia Wang, Jinghang Zhang, Jian Yu, Yongxi Zhang, Xianwei Wang, Jiateng Zhong. COL1A1: A potential therapeutic target for colorectal cancer expressing wild-type or mutant KRAS. International Journal of Oncology 2018; doi: 10.3892/ijo.2018.4536
|
| 39 |
Wei-Hung Hung, Jia-Huei Zheng, Kuen-Chan Lee, Er-Chieh Cho. Doxorubicin conjugated AuNP/biopolymer composites facilitate cell cycle regulation and exhibit superior tumor suppression potential in KRAS mutant colorectal cancer. Journal of Biotechnology 2019; 306: 149 doi: 10.1016/j.jbiotec.2019.09.015
|
| 40 |
Harvinder Kour Khera, Koustav Maity. Next Generation Biomanufacturing Technologies. ACS Symposium Series 2019; 1329: 109 doi: 10.1021/bk-2019-1329.ch006
|
| 41 |
Shing Fung Lee, Horace C. W. Choi, Sik Kwan Chan, Ka On Lam, Victor H. F. Lee, Irene O. L. Wong, Chi Leung Chiang. Cost-Effectiveness of Anti-Epidermal Growth Factor Receptor Therapy Versus Bevacizumab in KRAS Wild-Type (WT), Pan-RAS WT, and Pan-RAS WT Left-Sided Metastatic Colorectal Cancer. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.651299
|
| 42 |
Aitor Rodriguez-Casanova, Nicolás Costa-Fraga, Aida Bao-Caamano, Rafael López-López, Laura Muinelo-Romay, Angel Diaz-Lagares. Epigenetic Landscape of Liquid Biopsy in Colorectal Cancer. Frontiers in Cell and Developmental Biology 2021; 9 doi: 10.3389/fcell.2021.622459
|
| 43 |
Heena Singla, Abhilash Ludhiadch, Raman Preet Kaur, Harish Chander, Vinod Kumar, Anjana Munshi. Recent advances in HER2 positive breast cancer epigenetics: Susceptibility and therapeutic strategies. European Journal of Medicinal Chemistry 2017; 142: 316 doi: 10.1016/j.ejmech.2017.07.075
|
| 44 |
Tomi Akinyemiju. Epigenetic Mechanisms in Cancer. 2018; : 223 doi: 10.1016/B978-0-12-809552-2.00009-7
|
| 45 |
Giuseppe Sammarco, Gaetano Gallo, Giuseppina Vescio, Arcangelo Picciariello, Gilda De Paola, Mario Trompetto, Giuseppe Currò, Michele Ammendola. Mast Cells, microRNAs and Others: The Role of Translational Research on Colorectal Cancer in the Forthcoming Era of Precision Medicine. Journal of Clinical Medicine 2020; 9(9): 2852 doi: 10.3390/jcm9092852
|
| 46 |
Fortunato Ciardiello, Fred R. Hirsch, Robert Pirker, Enriqueta Felip, Christian Valencia, Egbert F. Smit. The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer. Cancer Treatment Reviews 2024; 122: 102664 doi: 10.1016/j.ctrv.2023.102664
|
| 47 |
Cleo Keppens, Elisabeth M. C. Dequeker, Simon J. Patton, Nicola Normanno, Francesca Fenizia, Rachel Butler, Melanie Cheetham, Jennifer A. Fairley, Hannah Williams, Jacqueline A. Hall, Ed Schuuring, Zandra C. Deans. International pilot external quality assessment scheme for analysis and reporting of circulating tumour DNA. BMC Cancer 2018; 18(1) doi: 10.1186/s12885-018-4694-x
|
| 48 |
Alessandro Ottaiano, Monica Capozzi, Salvatore Tafuto, Alfonso De Stefano, Chiara De Divitiis, Carmela Romano, Antonio Avallone, Guglielmo Nasti. Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice. Frontiers in Oncology 2019; 9 doi: 10.3389/fonc.2019.00766
|